| Click here to see a web copy of this news release | |||||
|
FOR IMMEDIATE RELEASE
Biden's Prostate Cancer and a 92-Year-Old Survivor: Rethinking Treatment Through Metabolic Cancer TherapyBy Richard Z. Cheng, M.D., Ph.D.📌 Introduction: A Familiar Diagnosis, a Missed Therapeutic OpportunityPresident Joe Biden's reported diagnosis of advanced metastatic prostate cancer has stirred concern worldwide. At age 82, he reportedly faces aggressive disease-Gleason score 9 with bone metastases-findings that typically carry a poor prognosis. The White House assures the public that the cancer is "hormone-sensitive" and "responding well" to conventional therapy. But this standard approach-primarily hormone blockade and palliative care-raises a deeper question: Is this truly the best we can do? The answer is no. A growing body of evidence now supports a fundamentally different therapeutic model: Cancer as a metabolic disease. Rather than viewing cancer as a purely genetic disorder, the metabolic model identifies mitochondrial dysfunction, chronic inflammation, and toxin-induced oxidative stress as core drivers of cancer progression. Metabolic cancer therapy addresses these root causes through a comprehensive and integrative approach:
This is not merely a preventative concept-it is an active, real-world therapeutic strategy that has helped patients with advanced cancers, including metastatic prostate cancer, not only extend survival but also regain quality of life. As the world watches President Biden's medical journey, this is the time to ask: Why is metabolic therapy still missing from mainstream cancer care? 📖 The Metabolic Theory of Cancer: A Paradigm ShiftThe foundation of our approach draws upon the groundbreaking work of Dr. Thomas N. Seyfried, professor of biology at Boston College and author of the influential book, Cancer as a Metabolic Disease. Seyfried's research builds on the original theory proposed by Nobel laureate Otto Warburg, who observed that cancer cells primarily rely on aerobic glycolysis-the fermentation of glucose-even in the presence of oxygen, a hallmark of dysfunctional mitochondria.
Thomas N. Seyfried, Richard Z. Cheng Seyfried's thesis challenges the dominant genetic mutation model of cancer and reframes it as a metabolic disease, rooted in mitochondrial dysfunction and energy dysregulation. This paradigm explains why dietary and metabolic interventions-especially ketogenic diets, glycolysis inhibitors, and mitochondrial support-can be powerful therapeutic tools. It was under this framework that our team developed and implemented a real-world integrative metabolic cancer therapy protocol that has changed lives-including one particularly striking case. 🧬 Integrative Metabolic Cancer Therapy: A Real-Life Case from the Front LinesOne of our most compelling success stories is Mr. Z, a man diagnosed in 2015 at age 86 with widespread metastatic prostate cancer to the bones and liver-a scenario strikingly similar to President Biden's. He received standard care-including surgery, chemotherapy, and hormonal castration-and remained disease-free for about a year, until the cancer returned violently in early 2018 with a dramatic PSA spike (>100), severe systemic pain, delirium, and fecal incontinence. His family was preparing for his imminent passing. His daughter heard of our approach and came to seek our help. They chose a different path: Integrative Metabolic Cancer Therapy. Under our care, Mr. Z began a multifaceted program inspired by the metabolic theory of cancer:
The results were extraordinary:
This is not an isolated anecdote. We have cared for patients with brain, lung, liver, breast, ovarian, hematologic, and other cancers using this metabolic framework. It is a demonstration of the power of addressing root causes, restoring metabolic integrity, and supporting-not suppressing-the body's natural defenses. 🛑 The Missed Opportunity in Conventional CareStandard therapies for prostate cancer-surgery, hormone blockade, radiation, chemotherapy-can be helpful but are incomplete. They often fail to address:
In President Biden's case, we hope for a full recovery. But we also urge his medical team-and the public at large-not to overlook the scientifically grounded, life-extending tools available through orthomolecular and metabolic medicine. 🔬 What Could Be Done-NowWhether facing early-stage or advanced prostate cancer, orthomolecular and metabolic strategies offer evidence-supported approaches to improve outcomes, restore metabolic control, and support long-term resilience:
📣 Conclusion: We Must Do BetterPresident Biden's diagnosis is not just a personal challenge-it's a national signal. Cancer is now the second leading cause of death worldwide, and the current model is failing too many. It's time to integrate what we know from decades of orthomolecular and metabolic research into mainstream care. Not later-now. Because cancer is not just a genetic accident. It is, in large part, a metabolic failure. Let's start treating it that way. About the AuthorRichard Z. Cheng, M.D., Ph.D. - Editor-in-Chief, Orthomolecular Medicine News Service
Orthomolecular MedicineOrthomolecular medicine uses safe, effective nutritional therapy to fight illness. For more information: http://www.orthomolecular.org Find a DoctorTo locate an orthomolecular physician near you: http://orthomolecular.org/resources/omns/v06n09.shtml The peer-reviewed Orthomolecular Medicine News Service is a non-profit and non-commercial informational resource. Editorial Review Board:
Jennifer L. Aliano, M.S., L.Ac., C.C.N. (USA)
Comments and media contact: editor@orthomolecular.org OMNS welcomes but is unable to respond to individual reader emails. Reader comments become the property of OMNS and may or may not be used for publication. Click here to see a web copy of this news release: https://orthomolecular.acemlna.com/p_v.php?l=1&c=432&m=387&s=bad97c655476f96a390a72c05a742011 |
|||||
|
This news release was sent to _t.e.s.t_@example.com. If you no longer wish to receive news releases, please reply to this message with "Unsubscribe" in the subject line or simply click on the following link: unsubscribe . To update your profile settings click here . This article may be reprinted free of charge provided 1) that there is clear attribution to the Orthomolecular Medicine News Service, and 2) that both the OMNS free subscription link http://orthomolecular.org/subscribe.html and also the OMNS archive link http://orthomolecular.org/resources/omns/index.shtml are included.
|
|||||
